Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis - Raised $8.8 million in gross proceeds from private placement and warrant inducement financings... Read More

Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata... Read More

SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's... Read More

XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne Over 30 million acne patients seek treatment in the U.S. each year SAN DIEGO , March 26, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq:... Read More

Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - - Raised $2.55 million in gross proceeds from a private placement... Read More

STAR-1 topline results expected by the end of March 2025 Over 30 million acne patients seek treatment in the U.S. each year XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America SAN DIEGO , March 4, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical... Read More

This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis SAN DIEGO, CA /... Read More

Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community SAN DIEGO, CA / ACCESS Newswire / January 29, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today... Read More

SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded... Read More

SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded warrants in lieu... Read More

The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis If successful, the Companies may explore clinical development in additional indications Xyngari ™ with Daxxify® has the potential to be the first approved needle-free intradermal delivery of a botulinum toxin product SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / ACCESS Newswire / January... Read More

Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 SAN DIEGO, CA / ACCESSWIRE / December 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today... Read More

This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy SAN DIEGO, CA / ACCESSWIRE / December... Read More

STAR-1 topline results expected in March 2025 Over 30 million acne patients seek treatment in the U.S. each year Phase 2b for DMT310 achieved statistically significant results for all primary endpoints SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin... Read More

Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial Dermata continues discussions with potential botulinum toxin partners for DMT410 Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Dermata Therapeutics , Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a late-stage... Read More

SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the Company's CEO, Gerry Proehl, will present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15, 2024, at... Read More

Dermata raises approximately $7.8 million in gross proceeds since May 2024 - expected to fund its operations into the second quarter of 2025 SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announcedthe closing of its... Read More

SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,912,569 shares of common stock (or pre-funded warrant in lieu... Read More

SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be presenting at the H.C. Wainwright 26 th Annual Global Investment Conference, being held September 9-11, 2024. The in-person venue for the event is the Lotte... Read More

DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients Dermata continues discussions with potential botulinum toxin partners for DMT410 Raised $2.3 million in net proceeds from financing completed in 2Q 2024 SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Dermata Therapeutics , Inc. (Nasdaq:DRMA, DRMAW)("Dermata," or the "Company"), a late-stage biotechnology company... Read More

STAR-1 topline results expected in first quarter of 2025 About 30 million acne patients seek treatment in the U.S. each year DMT310, if approved, could be the first once-weekly topical product for the treatment of acne SAN DIEGO, CA / ACCESSWIRE / July 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and... Read More

SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the Company's... Read More

DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track Dermata continues discussions with potential botulinum toxin partners for DMT410 Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis SAN DIEGO, CA / ACCESSWIRE / May 15, 2024 / Dermata Therapeutics , Inc. (Nasdaq:DRMA) (Nasdaq;DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology... Read More

Dermata to provide a corporate update followed by a live question and answer session SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on April 3, 2024. This... Read More

Company to provide a corporate overview followed by a live question and answer session SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on February... Read More

This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis The Company is currently discussing partnership opportunities to advance development of DMT410 In 2022, the Japanese prevalence of hyperhidrosis was 10%, with approximately 6% having primary axillary hyperhidrosis SAN DIEGO, CA / ACCESSWIRE / January 4, 2024 / Dermata Therapeutics, Inc.... Read More

About 550 patients will be treated once weekly for 12 weeks STAR-1 topline results expected in first quarter of 2025 Acne affects about 50 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it... Read More

SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,472,095 shares of common stock,... Read More

DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients Topline results from STAR-1 clinical trial expected in Q1 2025 DMT310, if approved, may be the first once-weekly, topical acne treatment SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc . (NASDAQ:DRMA)... Read More

Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 Completed start-up activities to support DMT310 Phase 3 STAR-1 clinical trial in acne SAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Dermata Therapeutics , Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata," or the "Company"), a clinical-stage... Read More

SAN DIEGO, CA / ACCESSWIRE / August 31, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the H.C. Wainwright 25 th Annual Global Investment Conference, being held September 11-13, 2023. The in-person venue for the event is... Read More

Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 Phase 3 STAR-1 study is projected to start enrolling patients in the 2H 2023 SAN DIEGO, CA / ACCESSWIRE / August 10, 2023 / Dermata Therapeutics , Inc. (Nasdaq: DRMA; DRMAW) ("Dermata," or the "Company"), a clinical-stage biotechnology company... Read More

FDA established key elements of the DMT310 Phase 3 clinical program and delineated a potential regulatory pathway for approval of DMT310 - The DMT310 Phase 3 program will consist of two pivotal trials, STAR-1 and STAR-2 ( Spongilla Treatment of Acne Research Study )- The first patient in STAR-1 is planned to be enrolled in 2H of 2023 - SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA,... Read More

SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced today that Dermata's CEO, Gerald Proehl, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20 th... Read More

DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) DMT310 significantly reduced inflammatory lesions by 45% after only 4 treatments in patients with moderate-to-severe acne FDA responses to DMT310 End of Phase 2 meeting package expected by... Read More

SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced registered direct offering of an aggregate of 800,877 shares of its common stock (or common stock equivalents in lieu thereof),... Read More

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into a definitive agreement for the purchase and sale of... Read More

Dermata raised $5 million gross proceeds from a public offering in March 2023 Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 FDA agreed that Dermata's chemistry, manufacturing, and control ("CMC") procedures support the initiation of Phase 3 studies of DMT310 for the treatment of acne SAN DIEGO, CA / ACCESSWIRE / May 11, 2023 / Dermata Therapeutics , Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata," or... Read More

FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies Dermata also submitted an end of phase 2 meeting package to the FDA SAN DIEGO, CA / ACCESSWIRE / April 20, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it... Read More

SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced public offering of 1,618,123 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A... Read More

SAN DIEGO, CA / ACCESSWIRE / March 16, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the pricing of a public offering of 1,618,123 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to... Read More

End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 DMT410 partnering discussions ongoing SAN DIEGO, CA / ACCESSWIRE / February 21, 2023 / Dermata Therapeutics , Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the... Read More

Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not meet primary endpoints DMT310 produced no serious adverse events related to treatment Dermata remains on track to request an End of Phase 2 meeting with the FDA for DMT310 for the treatment of acne in the first quarter of 2023 SAN DIEGO, CA / ACCESSWIRE / December 5, 2022 / Dermata Therapeutics, Inc. ("Dermata" or the... Read More